[Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].
Fukuda
Akira
A
First Department of Internal Medicine, Osaka Medical College.
D000998:Antiviral Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D012254:Ribavirin / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
D000998:Antiviral Agents; D015415:Biomarkers; D012367:RNA, Viral; D012254:Ribavirin; D007372:Interferons